Published in J Neuropsychiatry Clin Neurosci on January 01, 2006
An odor-specific threshold deficit implicates abnormal intracellular cyclic AMP signaling in schizophrenia. Am J Psychiatry (2008) 2.53
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res (2013) 1.08
Scents and nonsense: olfactory dysfunction in schizophrenia. Schizophr Bull (2009) 1.08
Negative symptoms of schizophrenia correlate with impairment on the University of Pennsylvania smell identification test. Neurosci Res (2009) 0.99
Olfactory processing in schizophrenia, non-ill first-degree family members, and young people at-risk for psychosis. World J Biol Psychiatry (2011) 0.96
Reduced posterior nasal cavity volume: a gender-specific neurodevelopmental abnormality in schizophrenia. Schizophr Res (2007) 0.86
Olfaction in the psychosis prodrome: electrophysiological and behavioral measures of odor detection. Int J Psychophysiol (2013) 0.85
Olfactory physiological impairment in first-degree relatives of schizophrenia patients. Schizophr Res (2008) 0.85
α7-Nicotinic acetylcholine receptor: role in early odor learning preference in mice. PLoS One (2012) 0.81
Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra. J Neurol (2017) 0.76
Unilateral olfactory sensitivity in multiple sclerosis. Physiol Behav (2016) 0.75
Impact of in-scanner head motion on multiple measures of functional connectivity: relevance for studies of neurodevelopment in youth. Neuroimage (2012) 4.84
An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. Neuroimage (2012) 4.30
Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med (2006) 4.00
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry (2005) 3.78
COMPARE: classification of morphological patterns using adaptive regional elements. IEEE Trans Med Imaging (2007) 3.72
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) (2011) 3.62
Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell (2013) 3.26
A method for obtaining 3-dimensional facial expressions and its standardization for use in neurocognitive studies. J Neurosci Methods (2002) 3.25
Sex differences in the structural connectome of the human brain. Proc Natl Acad Sci U S A (2013) 3.06
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr Bull (2009) 2.98
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry (2003) 2.69
Whole-brain morphometric study of schizophrenia revealing a spatially complex set of focal abnormalities. Arch Gen Psychiatry (2005) 2.59
A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J Neurosci Methods (2009) 2.55
Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology (2012) 2.54
An odor-specific threshold deficit implicates abnormal intracellular cyclic AMP signaling in schizophrenia. Am J Psychiatry (2008) 2.53
An fMRI study of facial emotion processing in patients with schizophrenia. Am J Psychiatry (2002) 2.50
Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest (2004) 2.46
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry (2003) 2.43
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J Immunol (2008) 2.22
Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry (2014) 2.15
Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement (2012) 2.13
Differences in facial expressions of four universal emotions. Psychiatry Res (2004) 2.11
Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol (2011) 2.09
Working memory for complex figures: an fMRI comparison of letter and fractal n-back tasks. Neuropsychology (2002) 2.07
An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05
The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry (2013) 2.04
Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc (2004) 2.00
Leftward asymmetry in relative fiber density of the arcuate fasciculus. Neuroreport (2005) 1.96
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2011) 1.93
Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc (2008) 1.92
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87
Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A (2010) 1.85
Translational research in medication development for nicotine dependence. Nat Rev Drug Discov (2007) 1.81
The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med (2007) 1.79
Brain activation during facial emotion processing. Neuroimage (2002) 1.76
Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res (2011) 1.73
Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol (2003) 1.71
Sex differences in temporo-limbic and frontal brain volumes of healthy adults. Cereb Cortex (2002) 1.69
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci (2005) 1.68
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68
Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr Bull (2006) 1.64
Event-related fMRI of frontotemporal activity during word encoding and recognition in schizophrenia. Am J Psychiatry (2004) 1.64
Ketamine modulates theta and gamma oscillations. J Cogn Neurosci (2010) 1.63
The other-race effect in face processing among African American and Caucasian individuals with schizophrenia. Am J Psychiatry (2008) 1.63
Impairment in the specificity of emotion processing in schizophrenia. Am J Psychiatry (2006) 1.58
Validating γ oscillations and delayed auditory responses as translational biomarkers of autism. Biol Psychiatry (2010) 1.58
Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Mov Disord (2011) 1.57
Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology (2011) 1.57
The Penn Conditional Exclusion Test: a new measure of executive-function with alternate forms of repeat administration. Arch Clin Neuropsychol (2004) 1.57
Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One (2011) 1.54
Age-related differences in brain activation during emotional face processing. Neurobiol Aging (2002) 1.54
A genome screen for quantitative trait loci influencing schizophrenia and neurocognitive phenotypes. Am J Psychiatry (2008) 1.51
A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology (2004) 1.51
Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord (2008) 1.49
Levels-of-processing effect on frontotemporal function in schizophrenia during word encoding and recognition. Am J Psychiatry (2005) 1.47
Catatonia in DSM-5. Schizophr Res (2013) 1.43
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm (2006) 1.42
Unaffected family members and schizophrenia patients share brain structure patterns: a high-dimensional pattern classification study. Biol Psychiatry (2007) 1.40
Heterogeneous impact of motion on fundamental patterns of developmental changes in functional connectivity during youth. Neuroimage (2013) 1.39
Alterations of fronto-temporal connectivity during word encoding in schizophrenia. Psychiatry Res (2007) 1.38
Social cognition deficits among individuals at familial high risk for schizophrenia. Schizophr Bull (2009) 1.36
Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology (2002) 1.36
Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med (2007) 1.35
Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol (2004) 1.34
The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol (2006) 1.32
Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord (2005) 1.32
Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2013) 1.30
Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol (2003) 1.30
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol (2010) 1.29
Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res (2008) 1.29
Definition and description of schizophrenia in the DSM-5. Schizophr Res (2013) 1.28
Facial emotion perception in depression and bipolar disorder: a quantitative review. Psychiatry Res (2011) 1.27
Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol (2011) 1.26
Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res (2006) 1.25
Explicit identification and implicit recognition of facial emotions: I. Age effects in males and females across 10 decades. J Clin Exp Neuropsychol (2008) 1.25